TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01937299

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as a placebo comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Travoprost 0.004% ophthalmic solution
Study: NCT00091858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: 6.75 mcg/kg Q4W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Q4W
Study: NCT03640819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tattooing of biopsied node
Description: Tattooing (marking) of biopsied node with carbon dye (SPOT dye) at the time of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
Study: NCT03167918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Dobesilate
Description: gave each patient 0.5 g bid，

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuefuzhuyu Decoction
Description: gave each patient100 ml bid，po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuefuzhuyu Decoction & Calcium dobesilate
Description: gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: gave each patient 1000 mg, bid, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: gave each patient 1000 mg, bid, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: gave each patient 1000 mg, bid, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin Tablets
Description: gave each patient 0.5 mg bid, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin Tablets
Description: gave each patient 0.5 mg bid, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin Tablets
Description: gave each patient 0.5 mg bid, PO
Study: NCT06370793

Intervention type: OTHER
Intervention: Patient with schizophrenia without intervention
Description: Patients with schizophrenia identified based on exposures of interest to the study
Study: NCT04343144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection
Description: Treatment consists of an infusion of OPDIVO® 3mg/kg on day 1 (D1).
Study: NCT03962829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mCPP
Description: Healthy participants administrate one capsule of mCPP (30mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Healthy participants administrate one capsule of placebo (containing lactose)
Study: NCT00655889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Fibroblasts (azficel-T)
Description: 1. Collection of biopsy from palate~2. Papillary priming procedure~3. Seven injection treatments to target sites~4. Performance of study assessments (investigator and subject)
Study: NCT03479905

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Salter nasal cannula
Description: Oxygen will be delivered via standard nasal cannula during colonoscopy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Face mask
Description: Oxygen will be delivered via face mask during colonoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula
Description: A high flow nasal cannula will be placed on the patient at a setting of FiO2 100% and titrated up to 60L/min depending on patient tolerance. 60 L/min is the max flow rate and will be used as tolerated for maximum benefit.
Study: NCT02255747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Study: NCT03183817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred care at distance
Description: Person-centred care at distance through an eHealth platform
Study: NCT03087240

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dental Prophylaxis
Description: Prevention and treatment of periodontal diseases by cleaning of the teeth in the dental office using the procedures of dental scaling and dental polishing. The treatment includes plaque detection, removal of supra- and subgingival plaque and calculus, as well as motivation and demonstration for establishing a sufficient oral hygiene.
Study: NCT01888900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUAL
Description: Asunaprevir and Daclatsvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QUAD
Description: Asunaprevir, daclatsvir, peginterferon and ribavirin
Study: NCT03087240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Prophylaxis
Description: Prevention and treatment of periodontal diseases by cleaning of the teeth in the dental office using the procedures of dental scaling and dental polishing. The treatment includes plaque detection, removal of supra- and subgingival plaque and calculus, as well as motivation and demonstration for establishing a sufficient oral hygiene.
Study: NCT01281696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, etoposide, cisplatin
Description: Bevacizumab (15mg/kg) on D1, etoposide (70mg/m2) on D2-D4, cisplatin (70mg/m2) on D2; 21 days a cycle, for a maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate
Description: Additional intrathecal methotrexate only given in patients with leptomeningeal metastasis
Study: NCT03148366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin based sequential therapy
Description: D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bismuth quadruple therapy for 10 days (BQ)
Description: D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
Study: NCT04780165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blephademodex
Description: During the first 28 days of the trial, subjects will use one Blephademodex® eyelid hygiene wipe every evening per eye to clean the eyelids of both their eyes. At the start of the second period the Investigator will assess based on the GDS if the condition is resolved and manage accordingly: subjects will either continue with this regime if GDS is unchanged (further treatment phase) or revert to Blephaclean wipes every evening instead (maintenance phase), again to clean the eyelids of both their eyes.
Study: NCT02579213

Intervention type: OTHER
Intervention: observational study done only in women candidate for amniocentesis
Description: As a part of routine test in women with obstetrical indication for amniocentesis, we take 30 cc of amniotic fluid. only additional 3 ml of the amniotic fluid are needed for examination by electronic sensors.
Study: NCT03178643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proguanil Oral Tablet
Description: Dosing of daily proguanil will be approximately 3mg/kg/day,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ)
Description: Age 1-5 on Day 1: One tablet 500/25mg SP and one tablet 153mg AQ Day 2 and Day 3: one tablet 153 mg AQ only each day For ages 6-10: Day 1 - 1.5 tablets 500/25mg SP and 1.5 tablets 153mg AQ Days 2 and 3: 1.5 tablets 153mg AQ only each day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-Piperaquine (DP)
Description: 3) The weight-based dosing of tablets of 40/320mg of DP is described below:~Weight (kg) No. of 40/320mg tabs DP daily for 3 days~≤ 5 ¼ 6-10 ½ 11-14 ¾ 15-19 1 20-23 1 ¼ 24-25 1 ½
Study: NCT02347423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV Vaccine SSI
Study: NCT00876161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
Study: NCT03916939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathy
Description: osteopathy treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: simulated osteopathy
Description: simulated osteopathic sessions
Study: NCT03082118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vesair Bladder Control System
Description: Intravesical balloon
Study: NCT00876161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Study: NCT01242826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose of 0.3 U/kg BIAsp 50 for subcutaneous (under the skin) injection
Study: NCT00720759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine + distributed treatment
Description: Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: D-cycloserine + condensed treatment
Description: Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
Study: NCT00575120

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ischemia reperfusion
Description: reperfusion after a 15 min. lasting cuff induced arm ischemia
Study: NCT00730275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: matching placebo
Description: Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
Study: NCT02548598

Intervention type: PROCEDURE
Intervention: Endoscopic sinus surgery
Description: This is an observational trial of patients with and without asthma who have concomitant chronic rhinosinusitis requiring endoscopic sinus surgery.
Study: NCT00720759

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + distributed treatment
Description: Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + condensed treatment
Description: Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with placebo administered before each treatment session
Study: NCT01034553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurora A kinase inhibitor MLN8237
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT04646278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperemic stimuli
Description: Hyperemic simuli of coronary flow by adenosine or nicorandil injection
Study: NCT02318940

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: central venous catheter
Description: installation of Central venous catheter ultrasound guided
Study: NCT02548598

Intervention type: PROCEDURE
Intervention: Endoscopic sinus surgery
Description: This is an observational trial of patients with and without asthma who have concomitant chronic rhinosinusitis requiring endoscopic sinus surgery.

Intervention type: PROCEDURE
Intervention: Endoscopic sinus surgery
Description: This is an observational trial of patients with and without asthma who have concomitant chronic rhinosinusitis requiring endoscopic sinus surgery.
Study: NCT02318940

Intervention type: DEVICE
Group type: OTHER
Intervention: central venous catheter
Description: installation of Central venous catheter landmark guided
Study: NCT03523637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive Exposure
Description: The intervention Interoceptive Exposure (IE) is an exposure to bodily sensations used in treatment of variety of problems where body sensations are experienced as threatening. This psychological technique is about focusing attention on pain, 'staying with the pain' without trying to escape it.
Study: NCT01449500

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L. reuteri
Description: Chewable tablet, one tablet/day for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Chewable tablet, one tablet per day for 28 days
Study: NCT01107821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Engenex™ pump and Bio-Dome™ Wound Dressing
Description: Engenex™ pump and Bio-Dome™ Wound Dressing is used.
Study: NCT00356408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol (CDP870), an anti-tumor necrosis factor (TNF)α, humanized antibody Fab' fragment - polyethylene glycol conjugate, solution for injection, in 10 mM sodium acetate buffer and 125 mM sodium chloride, pH 4.7, supplied in 3 mL vials with a fill of 1.4 mL (an extractable volume of 1 mL corresponds to a dose of 200 mg).~Dosing is every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2.
Study: NCT01015547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate
Description: IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of DMARDs
Description: IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate alone
Description: Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
Study: NCT01010334

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard of care
Description: All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.
Study: NCT02100787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraTears lubricating drops
Description: A over-the-counter lubricating eye drop to be used 1 drop in both eyes 4 times a day (QID) for 8 weeks
Study: NCT03746509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Vibration (Treatment)
Description: The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
Study: NCT00911937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: Fesoterodine 4mg and 8 mg tablets taken daily.
Study: NCT00911937

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sham 4mg and 8 mg tables taken daily.
Study: NCT03746509

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Vibration (Comparator)
Description: The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Vibration (Comparator)
Description: The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
Study: NCT00497107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT, Calcium Folinate, PSK

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UFT, Calcium Folinate
Study: NCT01235221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB041 (Fampridine-SR)
Description: 10 mg twice a day (BID) sustained-release (SR) tablets by mouth for up to 27 months (in addition to treatment in previous studies) or until the product is commercially available, whichever comes first. Doses of study treatment must be spaced at least 12 hours apart.
Study: NCT04075344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Infection control programme
Description: 12 weekse educational programme with 6 sessions, 45 minutes per session will be provided to experimental group RCHEs staff
Study: NCT01872962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin (Induction chemotherapy)
Description: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
Study: NCT01769963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research diet
Description: Participants will be provided specially prepared meals to eat at home for three weeks. During the first week, participants will eat foods that have standard amounts of AGEs in them (this is called the control diet). During the second and third weeks, participants will eat the same foods, only they will be prepared in our kitchen in a way that limits the amount of AGEs in them (called the intervention diet).
Study: NCT04265807

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Remote Ischemic Conditioning
Description: A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins. inflation to 200 mmHg followed by 5-mins. deflation of a blood pressure cuff on a upper extremity. The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
Study: NCT01872962

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT and concurrent cisplatin
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT and concurrent cisplatin
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
Study: NCT03783065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol was administrated orally while keeping monitoring heart rate and blood pressure daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol was administrated orally while keeping monitoring heart rate and blood pressure daily.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy and pericardial devascularization
Description: Including splenectomy and pericardial devascularizaion under laparoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic therapy
Description: Either endoscopic variceal ligation (EVL) or cyanoacrylate injection was applied according to the condition of varices
Study: NCT00700427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine hydrochloride
Description: Oral 40-100 mg/day